Reviewing Dicerna Pharmaceuticals Inc. (DRNA)’s and argenx SE (NASDAQ:ARGX)’s results

We will be contrasting the differences between Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) and argenx SE (NASDAQ:ARGX) as far as profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dicerna Pharmaceuticals Inc. 14 84.10 N/A -1.70 0.00
argenx SE 131 0.00 N/A -1.73 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 demonstrates the return on assets, net margins and return on equity of Dicerna Pharmaceuticals Inc. and argenx SE.

Net Margins Return on Equity Return on Assets
Dicerna Pharmaceuticals Inc. 0.00% -66.1% -37.2%
argenx SE 0.00% 0% 0%

Analyst Recommendations

In next table is delivered Dicerna Pharmaceuticals Inc. and argenx SE’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Dicerna Pharmaceuticals Inc. 0 0 1 3.00
argenx SE 0 0 2 3.00

Dicerna Pharmaceuticals Inc.’s upside potential is 50.58% at a $22 average target price. argenx SE on the other hand boasts of a $171.5 average target price and a 37.32% potential upside. Based on the results delivered earlier, Dicerna Pharmaceuticals Inc. is looking more favorable than argenx SE, analysts opinion.

Institutional and Insider Ownership

Roughly 90% of Dicerna Pharmaceuticals Inc. shares are held by institutional investors while 55.81% of argenx SE are owned by institutional investors. About 8.38% of Dicerna Pharmaceuticals Inc.’s share are held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Dicerna Pharmaceuticals Inc. -10.03% -12.68% 8.52% 35.62% 9.57% 27.5%
argenx SE -1.84% -1.67% 13.7% 35.71% 53.91% 46.21%

For the past year Dicerna Pharmaceuticals Inc.’s stock price has smaller growth than argenx SE.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.